The Dermatological Drugs Development Pipeline 2025

​Release Date: Q4' 2025
Number of Candidates: 216

The Dermatological Drugs Pipeline dataset provides a comprehensive, structured listing of emerging dermatology therapies. It includes candidate names, developers, indications, disease areas, drug types, administration routes, development phases, and descriptions. This dataset enables pharmaceutical executives and investors to track clinical progress, track emerging mechanisms, and identify opportunities across psoriasis, atopic dermatitis, alopecia, skin cancer, and other dermatological conditions.
​Figure: Distribution of Dermatological Pipeline Candidates by Developmental Phase (%)
The “Dermatological Drugs Pipeline 2025” excel sheet presents a look at the major drug candidates currently in the clinical pipeline.

The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the dermatological drugs market, profiling 216 future candidates.
Pricing: The pipeline excel data sheet is available for the following price: 
​Single User License: USD 1,200

Company Wide License (Single Site): USD 1,500
​
Company Wide License (Global Site): USD 2,500
For a Sample and Inquiries please contact: [email protected]
Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories: 
  • Candidate (Name)
  • Drug Developer(s)
  • Category/Therapeutic Area(s)​
    • ​Acne & Rosacea
      • Acne Vulgaris
      • ​​Papulopustular Rosacea
    • Alopecia
      • ​Alopecia Areata
      • Androgenetic Alopecia
    • Dermatitis
      • Atopic Dermatitis
      • Contact Dermatitis
    • Psoriasis
      • Nail Psoriasis
      • Plaque Psoriasis
      • Psoriatic Arthritis
    • Skin & Fungal Infections
      • ABSSSI (Acute Bacterial Skin and Skin Structure Infections) 
      • Onychomycosis
      • Skin and soft tissue infections (SSTIs)
    • Skin Cancer
      • BCC (Basal Cell Carcinoma)
      • Cutaneous T-cell lymphoma (CTCL)
      • Melanoma
      • MCC (Merkel Cell Carcinoma)
      • SCC (Squamous Cell Carcinoma)
    • Other Indications
      • Actinic Keratosis
      • Cutaneous Lupus Erythematosus (CLE) 
      • Dermatomyositis
      • EB (Epidermolysis Bullosa)
      • Pemphigus Vulgaris
      • Pruritus
      • ​Systemic scleroderma
      • Vitiligo
      • Warts
      • Urticaria
      • Others
    • Multiple Indications
  • Development Stage
    • Phase I
    • Phase I/II
    • Phase II
    • Phase II/III
    • Phase III
    • Pre-Clinical
    • Pre-Registration
List of Companies Covered:
The following companies and organizations have been mentioned in the pipeline:

3M
Abbott Laboratories
AbbVie
Abeona Therapeutics
Aclaris Therapeutics
Adaptimmune
AiCuris
Akros Pharma
Almirall
AltruBio
Amgen
Amryt Pharma (Chiesi Farmaceutici S.p.A)
AnaptysBio
AnnJi Pharmaceutical
Apotex
Arcutis Biotherapeutics
Asana BioSciences
ASLAN Pharmaceuticals
Astelia Therapeutics
AstraZeneca
Astria Therapeutics
Bausch Health Companies (Ortho Dermatologics)
Bayer Pharmaceuticals
Biofrontera
Biogen
BioMimetix
BioRay Pharmaceutical
Bio-Thera Solutions
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
BPGbio
Cadila Pharmaceuticals
Capella BioScience
Castle Creek Biosciences
Celgene
Celltrion
Cerbios-Pharma
Chugai Pharmaceutical
Cipher Pharmaceuticals
Clinuvel Pharmaceuticals
Cosmo Pharmaceuticals
CSL Behring
Cugene
Cumberland Pharmaceuticals
Daewoong Pharmaceutical
Debiopharm
Dermata Therapeutics
DermBiont
Eirion Therapeutics
Eli Lilly
EMD Serono
Exelixis
Fibrocell Science
G&E Herbal Biotechnology
Galapagos
Galderma
Galectin Therapeutics
Genentech (Roche)
Gilead Sciences
GSK (GlaxoSmithKline)
Hallux
Horizon Therapeutics
Hoth Therapeutics
Huya Bioscience
Ichnos Glenmark Innovation (IGI)
Immutep
Incyte Corporation
Innovation Pharmaceuticals
Ipsen
Janssen Biotech
Janssen Research & Development
Japan Tobacco (JT)
Jiangsu HengRui Medicine
Johnson & Johnson
Kiniksa Pharmaceuticals
Kintara Therapeutics
Krystal Biotech
Kyowa Kirin
LEO Pharma
Lipidor
Maruho
Medytox
Merck & Co
Merck KGaA
Moderna
Mycovia Pharmaceuticals
Nanology
Neumedicines
Nielsen BioSciences
Novartis
Oncolys Biopharma
Ono Pharmaceutical
Opsidio
Pelthos Therapeutics (Ligand Pharmaceuticals)
Pfizer
Philogen
Phio Pharmaceuticals
Photogen Technologies Inc.
Poli Group
Polichem
Polpharma Biologics
Priovant Therapeutics
ProQR Therapeutics
Provectus Biopharmaceuticals
Qurient
Ralexar Therapeutics
Ranbaxy Laboratories
Rani Therapeutics
Regeneron
Sanofi
Sol-Gel Technologies
Soligenix
Takeda
Taro Pharmaceuticals
Teva Pharmaceutical Industries
Timber Pharmaceuticals (Acquired by Leo Pharma)
Tioga Pharmaceuticals
UCB Biopharma
UNION Therapeutics
Vanda Pharmaceuticals
Verrica Pharamceuticals
VidacPharma
Villaris Therapeutics (Incyte Corporation)